Fusion Antibodies plc (LSE:FAB) has reported interim results showing narrower losses and increased investment in R&D for the first half of FY2026, even as revenue fell year-on-year. The company underscored notable progress on its OptiMAL® platform, including a successful validation study with the U.S. National Cancer Institute and the award of a U.S. patent. Preparations for the commercial rollout of OptiMAL® remain on schedule, supported by encouraging early feedback from potential customers and the prospect of building a scalable, licensing-led revenue stream. Fusion is positioning itself to benefit from an improving market backdrop and intends to broaden its offering with new libraries geared toward diagnostic and veterinary applications.
The company’s outlook continues to be weighed down by financial strain and soft technical indicators. Persistent losses, tight cash flow, and negative profitability remain key challenges, while bearish trading signals point to continued downside risk. Valuation metrics reflect these pressures, contributing to a cautious overall assessment.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Northern Ireland–based Contract Research Organisation specializing in antibody discovery, engineering, and expression services for human and veterinary therapeutics as well as diagnostic applications. Its capabilities span discovery, development, optimization, characterization, and small-scale production, along with antigen design, expression, purification, and sequencing. The company has completed numerous humanization projects for leading global pharmaceutical firms and is focused on accelerating the antibody-driven drug discovery pipeline.
Leave a Reply